Context and Objective: Prostate cancer (PCa) is hormone-dependent cancer. In our area, most patients often arrive at the locally advanced stage or the metastatic stage. This justifies the choice of androgen deprivation as the mode of treatment. The objective of this study was to describe the socio-demographic characteristics of patients with PCa. Identifying the period during which the disease remains susceptible to androgen deprivation. Assessing the patient’s prognosis in terms of survival. Methods: This is a retrospective observational study of the course of patients managed for PCa. It involved 51 cases and was conducted at the Pointe à Pitre clinic (CPAP) in Matete Township during a period of 4 years (from March 2014 to June 2018). Results: The mean age of patients was 69.4 ± 9.7 years (40 - 92 years); 39.2% of patients with PCa were aged between 70 - 79 years; 45.1% had consulted for dysuria and 25.5% were hypertensive. All had performed the prostate biopsy, 47.1% were diagnosed at the metastatic stage, with PSA ≥ 100 ng/ml, Gleason scores 8 - 10, and clinical-stage TNM 3 - 4. About 51% were subjected to androcure, 23.5% had been surgically cased and 3.9% had undergone radical prostatectomy. 41.1% had resisted castration within a median of 1.4 years of response to treatment. The median survival was 30 months, with a mean survival of 26.6 months. Conclusion: Prostate cancer involved most of the patients in the age bracket of 70 to 79 years. The diagnosis was performed lately with a high resistance rate of castration and median survival of 30 months.
KeywordsDeprivationProstate Cancer (PCa)Pointe àPitre Clinic (CPAP)
Jema, A., Bray, F., Center, M., Ferlay, J., Ward, E. and Forman, D. (2011) Cancer Statistics, 2010. CA: A Cancer Journal for Clinicians, 61, 69-90. https://doi.org/10.3322/caac.20107
Ferlay, J., Parkin, D.M. and Steliarova-Faucher, E. (2010) Estimates of the Cancer Incidence and Mortality in Europe at 2008. European Journal of Cancer, 46, 765-781. https://doi.org/10.1016/j.ejca.2009.12.014
Brureau, L., Multigner, L., Wallois, A., Verhoest, G., Ndong, J.R., Fofana, M. and Blanchet, P. (2009) Cancer de la prostate en Guadeloupe: Incidence, mortalité, caractéristiques cliniques et anatomopathologiques. Bulletin du Cancer, 96, 165-170. https://doi.org/10.1684/bdc.2008.0811
Heidenreich, A., Aus, G., Bolla, M., Joniau, S., et al. (2008) European Association of Urology Guidelines on Prostate Cancer. European Urology, 53, 68-80. https://doi.org/10.1016/j.eururo.2007.09.002
Monika, J. (2007) Etude de l’Impact de mutations du domaine de liaison à l’ADN sur les fonctions du récepteur des androgènes dans le cancer de la prostate. Thèse de Doctorat en Science du vivant, Université Louis Pasteur Starsbourg, 258, 18-23.
Ruffion, A., Pointaine, E. and Staerman, F. (2003) Traitement hormonal du cancer de la prostate métastatique. Progrès en Urologie, 13, 334-341.
Culling, Z. (2013) Rôle of the androgen receptor axis in prostat cancer. Urology, 62, 21-26. https://doi.org/10.1016/S0090-4295(03)00698-8
Felderman, B. and Felderman, D. (2001) The Development of Androgen-Independent Prostate Cancer. Nature Reviews Cancer, 1, 34-35. https://doi.org/10.1038/35094009
Albertsen, P.C., Hanley, J.A., Gleason, D.F. and Barry, M.J. (1998) Competing Risk Analysis of Men Aged 55 to 74 Years at Diagnosis Managed Conservatively for Clinically Localized Prostate Cancer. JAMA, 280, 975-980. https://doi.org/10.1001/jama.280.11.975
NICE (2008) National Institute for Health and Clinical Excellence Guidelines: Prostate Cancer: Diagnosis and Treatment. National Collaborating Centre for Cancer, London.
Crawford, E.D. and Petrylak, D. (2010) Castration-Resistant Prostate Cancer: Descriptive yet Pejorative? Journal of Clinical Oncology, 28, 408. https://doi.org/10.1200/JCO.2010.28.7664
European Association of Urology (2009) Guidelines on Prostate Cancer. https://uroweb.org/wp-content/uploads/05-Prostate-Cancer.pdf
Kirby, M., Hirst, C. and Crawford, E.D. (2011) Characterising the Castration-Resistant Prostate Cancer Population: A Systematic Review. International Journal of Clinical Practice, 65, 1180-1192. https://doi.org/10.1111/j.1742-1241.2011.02799.x
Gjertson, C.K., et al. (2007) Local Control and Long-Term Disease-Free Survival for Stage D1 (T2-T4N1-N2M0) Prostate Cancer after Radical Prostatectomy in the PSA Era. Urology, 70, 723-727. https://doi.org/10.1016/j.urology.2007.05.014
Brureau, L., Moningo, D., Emeville, E., Ferdinand, S., Punga, A., Lufuma, S., Blanchet, P., Romana, M. and Multigner, L. (2016) Polymorphisms of Estrogen Metabolism Related Genes and Prostate Cancer Risk in Two Populations of African Ancestry. PLoS ONE, 11, e0153609. https://doi.org/10.1371/journal.pone.0153609
Sine, B., Bagayogo, N.A., Thiam, A., Sarr, A., Zakou, A.R., Faye, S.T., Fall, B., Sow, Y., Diao, B., Fall, P.A., Ndoye, A.K. and Ba, M. (2016) Cancers de la prostate de score de Gleason supérieur ou égal à 8: Evaluation de la survie des patients. African Journal of Urology, 22, 243-248. https://doi.org/10.1016/j.afju.2016.01.011
Moningo, D., Blanchet, P. and Maole, A.P. (2018) Profil Epidémiologique et Déterminants Génétiques du cancer de la prostate à Kinshasa. Ediditions universitaires européennes. 91-113.
Hwang, S.S., Chang, V.T., Alejandro, Y., Mulaparthi, S., et al. (2004) Study of Hormone Refractory Prostate Cancer: Hospital Care and Palliative Care Resource Use at a VA. Cancer Investigation, 22, 849-857. https://doi.org/10.1081/CNV-200039643
Smith, M.R., Kabbinavar, F., Saad, F., Hussain, A., et al. (2005) Natural History of Rising Serum Prostate-Specific Antigen in Men with Castrate Nonmetastatic Prostate Cancer. Journal of Clinical Oncology, 23, 2918-2925. https://doi.org/10.1200/JCO.2005.01.529
Botto, H., Rouprét, M., Mathieu, F. and Richard, F. (2007) Etude randomisée multicentrique comparant la castration médicale par triptoréline à la castration chirurgicale dans le traitement du cancer de la prostate localement avancé ou métastatique. Progrès en Urologie, 17, 235-239. https://doi.org/10.1016/S1166-7087(07)92270-8
Moreira, D.M., Howard, L.E., Sourbeer, K.N., Amarasekara, H.S., Chow, L.C., Cockrell, D.C., Hanyok, B.T., Aronson, W.J., Kane, C.J., Terris, M.K., Amling, C.L., Cooperberg, M.R., Liede, A. and Freedland, S.J. (2016) Predictors of Time to Metastasis in Castration-Resistant Prostate Cancer. Urology, 96, 171-176. https://doi.org/10.1016/j.urology.2016.06.011
Chtouk, M.A. (2016) Prise en charge du cancer de la prostate localement avancé et métastatique. Thèse du Doctorat en médecins, Université CADI AYYAD, Faculté de médecine et de Pharmacie, Marrakech, 11.
Rozet, F., Hennequin, C., Beauval, J.B., Beuzeboc, P., Cormier, L., Fromont, G., et al. (2016) CCAFU recommandations nationales sur le cancer de la prostate 2016-2018. Progrès en Urologie, 27, S95-S143. https://doi.org/10.1016/S1166-7087(16)30705-9
Hussain, M., Fizazi, K., Saad, F., Rathenborg, P., Shore, N., Ferreira, U., Ivashchenko, P., Demirhan, E., Modelska, K., De Phung, B.S., Krivoshik, A. and Sternberg, C.N. (2018) Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer. The New England Journal of Medicine, 378, 26. https://doi.org/10.1056/NEJMoa1800536
Ngandu, T.J., Kabongo, J.-M., Punga, M.A., Lebwaze, M.B., Moningo, D., Munabe, K.K.P. and Roux, J.J. (2015) Valeur du PSA dans le diagnostic du cancer de la prostate à Mbujimayi. Revue Médicale des Grands Lacs, 6, No. 4.
Di Francesco, S., Robuffo, I., Caruso, M., Giambuzzi, G., Ferri, D., Militello, A. and Toniato, E. (2019) Metabolic Alterations, Aggressive Hormone-Naïve Prostate Cancer and Cardiovascular Disease: A Complex Relationship. Medicina (Kaunas), 55, 62. https://doi.org/10.3390/medicina55030062
Hsing, A.W., Sakoda, L.C. and Chua, S. (2007) Obesity, Metabolic Syndrome, and Prostate Cancer. The American Journal of Clinical Nutrition, 86, 843-857. https://doi.org/10.1093/ajcn/86.3.843S
Tilg, H. and Moschen, A.R. (2008) Role of Adiponectin and PBEF/Visfatin as Regulators of Inflammation: Involvement in Obesity-Associated Diseases. Clinical Science, 114, 275-288. https://doi.org/10.1042/CS20070196
Häggström, C., Stocks, T., Ulmert, D., Bjørge, T., Ulmer, H., Hallmans, G., Manjer, J., Engeland, A., Nagel, G., Almqvist, M., Selmer, R., Concin, H., Tretli, S., Jonsson, H. and Stattin, P. (2012) Prospective Study on Metabolic Factors and Risk of Prostate Cancer. Cancer, 118, 199-206. https://doi.org/10.1002/cncr.27677
Gueye, S.M., Zeigler-Johnson, C.M., Friebel, T., et al. (2003) Clinical Characteristics of Prostate Cancer in African Americans, American Whites, and Senegalese Men. Urology, 61, 987-992. https://doi.org/10.1016/S0090-4295(02)02588-8
Niang, L., Ndoye, M., Ouattara, A., et al. (2013) Management of Prostate Cancer in Senegal; What Is Being Done? Progrès en Urologie, 23, 36-41. https://doi.org/10.1016/j.purol.2012.09.002
Punga-Maole, A.M., Moningo, D.M., Kayembe, P.K., Tshikuela, M.L. and Kabongo, J.M. (2008) Study of Prostate Cancer Screening in a Population of Employees of a Kinshasa Company in the Democratic Republic of Congo. Detection Rate and Nutritional and Geographical Risk Factors. Progrès en Urologie, 18, 512-518. https://doi.org/10.1016/j.purol.2008.04.009
Zhao, H., Coram, M.A., Nolley, R., Reese, S.W., Young, S.R. and Peehl, D.M. (2012) Transcript Levels of Androgen Receptor Variant AR-V1 or AR-V7 Do Not Predict Recurrence in Patients with Prostate Cancer at Indeterminate Risk for Progression. Journal of Urology, 188, 2158-2164. https://doi.org/10.1016/j.juro.2012.08.014
Smith, M.R., Cook, R., Lee, K.A. and Nelson, J.B. (2011) Disease and Host Characteristics as Predictors of Time to First Bone Metastasis and Death in Men with Progressive Castration-Resistant Non Metastatic Prostate Cancer. Cancer, 117, 2077-2085. https://doi.org/10.1002/cncr.25762
Parker, C., Nilsson, S., Heinrich, D., Helle, S.I., O’Sullivan, J.M., Fossa, S.D., Chodacki, A., Wiechno, P., Logue, J., Seke, M., et al. (2013) Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer. The New England Journal of Medicine, 369, 213-223. https://doi.org/10.1056/NEJMoa1213755
Bubendorf, L., et al. (2000) Metastatic Patterns of Prostate Cancer: An Autopsy Study of 1589 Patients. Human Pathology, 31, 578-583. https://doi.org/10.1053/hp.2000.6698
He, M., Liu, H.N., Cao, J.Y., Wang, Q., Xu, H.T. and Wang, Y.F. (2017) Predicting Castration-Resistant Prostate Cancer after Combined Androgen Blockade. Oncotarget, 8, 105458-105462. https://doi.org/10.18632/oncotarget.22246
Gillessen, S., Omlin, A., Attard, G., de Bono, J.S., Efstathiou, E., Fizazi, K., Halabi, S., Nelson, P.S., Sartor, O., Smith, M.R., Soule, H.R., Akaza, H., Beer, T.M., Beltran, H., Chinnaiyan, A.M., Daugaard, G., Davis, I.D., De Santis, M., Drake, C.G., Eeles, R.A., Fanti, S., Gleave, M.E., Heidenreich, A., Hussain, M., James, N.D., Lecouvet, F.E., Logothetis, C.J., Mastris, K., Nilsson, S., Oh, W.K., Olmos, D., Padhani, A.R., Parker, C., Rubin, M.A., Schalken, J.A., Scher, H.I., Sella, A., Shore, N.D., Small, E.J., Sternberg, C.N., Suzuki, H., Sweeney, C.J., Tannock, I.F. and Tombal, B. (2015) Management of Patients with Advanced Prostate Cancer: Recommandations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Annals of Oncology, 26, 1589-1604. https://doi.org/10.1093/annonc/mdv257
Szmulewitz, R.Z., Peer, C.J., Ibraheem, A., Martinez, E., Kozloff, M.F., Carthon, B., Harvey, R.D., Fishkin, P., Yong, W.P., Chiong, E., Nabhan, C., Karrison, T., Figg, W.D., Stadler, W.M. and Ratain, M.J. (2018) Prospective International Randomized Phase II Study of Low-Dose Abiraterone with Food versus Standard Dose Abiraterone in Castration-Resistant Prostate Cancer. Journal of Clinical Oncology, 36, 1389-1395. https://doi.org/10.1200/JCO.2017.76.4381
Ryan, C.J., Molina, A., Li, J., et al. (2013) Serum Androgens as Prognostic Biomarkers in Castration-Resistant Prostate Cancer: Results from an Analysis of a Randomized Phase III Trial. Journal of Clinical Oncology, 31, 2791-2798. https://doi.org/10.1200/JCO.2012.45.4595
Pilon, D., Queener, M., Lefebvre, P., et al. (2016) Cost per Median Overall Survival Month Associated with Abiraterone Acetate and Enzalutamide for Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer. Journal of Medical Economics, 19, 777-784. https://doi.org/10.3111/13696998.2016.1173042
Schweizer, M.T., Huang, P., Kattan, M.W., et al. (2013) Adjuvant Leuprolide with or without Docetaxel in Patients with High-Risk Prostate Cancer after Radical Prostatectomy (TAX-3501): Important Lessons for Future Trials. Cancer, 119, 3610-3618. https://doi.org/10.1002/cncr.28270
Ost, P., Bossi, A., Decaestecker, K., De Meerleer, G., Giannarini, G., Karnes, R.J., Roach, M. and Briganti, A. (2015) Metastasis-Directed Therapy of Regional and Distant Recurrences after Curative Treatment of Prostate Cancer: A Systematic Review of the Literature. European Urology, 67, 852-863. https://doi.org/10.1016/j.eururo.2014.09.004
Miyahira, A.K., Lang, J.M., Den, R.B., Garraway, I.P., Lotan, T.L., Ross, A.E., Stoyanova, T., Cho, S.Y., Simons, J.W., Pienta, K.J. and Soule, H.R. (2016) Multidisciplinary Intervention of Early, Lethal Metastatic Prostate Cancer: Report from the 2015 Coffey-Holden Prostate Cancer Academy Meeting. Prostate, 76, 125-139. https://doi.org/10.1002/pros.23107
Alemayehu, B., Buysman, E., Parry, D., Becker, L. and Nathan, F. (2010) Economic Burden and Health Care Utilization Associated with Castration-Resistant Prostate Cancer in a Commercial and Medicare Advantage US Patient Population. Journal of Medical Economics, 13, 351-361. https://doi.org/10.3111/13696998.2010.491435
Morgan, C., McEwan, P., Chamberlain, G., Cabrera, C. and Parry, D. (2010) Castration-Resistant Prostate Cancer (CRPC): A UK Epidemiology Study. Value Health, 13, A26. https://doi.org/10.1016/S1098-3015(10)72108-2
Berruti, A., Tucci, M., Mosca, A., Tarabuzzi, R., et al. (2005) Predictions Factors for Skeletal Complications in Hormone-Refractory Prostate Cancer Patients with Metastatic Bone Disease. British Journal of Cancer, 93, 633-638. https://doi.org/10.1038/sj.bjc.6602767
Halabi, S., Dutta, S., Tangen, C.M., Rosenthal, M., Petrylak, D.P., Thompson, I.M., Chi, K.N., Araujo, J.C., Logothetis, C., Quinn, D.I., Fizazi, K., Morris, M.J., Eisenberger, M.A., George, D.J., De Bono, J.S., Higano, C.S., Tannock, I.F., Small, E.J. and Kelly, W.K. (2019) Overall Survival of Black and White Men with Metastatic Castration-Resistant Prostate Cancer Treated with Docetaxel. Journal of Clinical Oncology, 37, 403-410. https://doi.org/10.1200/JCO.18.01279
Bianco, F.J., Wood, D.P., Cher, M.L., Powell, I.J., et al. (2003) Ten-Year Survival after Radical Prostatectomy: Specimen Gleason Score Is the Predictor in Organ-Confined Prostate Cancer. Clinical Prostate Cancer, 1, 242-247. https://doi.org/10.3816/CGC.2003.n.006
Cheville, J.C., Tindall, D., Boelter, C., et al. (2002) Metastatic Prostate Carcinoma, Clinical and Pathologic Features Associated with Cancer-Specific Survival. Cancer, 95, 1028-1036. https://doi.org/10.1002/cncr.10788
Sundi, D., Wang, V.M., Pierorazio, P.M., Han, M., Bivalacqua, T.J., Ball, M.W., Antonarakis, E.S., Partin, A.W., Schaeffer, E.M. and Ross, A.E. (2014) Very-High-Risk Localized Prostate Cancer: Definition and Outcomes. Prostate Cancer and Prostatic Diseases, 17, 57-63. https://doi.org/10.1038/pcan.2013.46
Chin, S.N., Wang, L., Moore, M. and Sridhar, S.S. (2010) A Review of the Patterns of Docetaxel Use for Hormone-Resistant Prostate Cancer at the Princess Margaret Hospital. Current Oncology, 17, 24-29. https://doi.org/10.3747/co.v17i2.482
Schröder, F.H. and Roobol, M.J. (2010) ERSPS and PLCO Prostate Cancer Screening Studies: What Are the Differences? European Urology, 58, 46-52. https://doi.org/10.1016/j.eururo.2010.03.033
Salomon, L., Azria, D., Bastide, C., Beuzeboc, P., Cormier, L., Cornu, F., et al. (2010) Comité de Cancérologie de l’AFU. Recommandations en onco-urologie: Cancer de la prostate. Progrès en Urologie, 20, S21. https://doi.org/10.1016/S1166-7087(10)70042-7
Bolla, M., Maingon, P., Carrie, C., et al. (2016) Short Androgen Suppression and Radiation Dose Escalation for Intermediate- and High-Risk Localized Prostate Cancer: Results of EORTC Trial 22991. Journal of Clinical Oncology, 34, 1748-1756. https://doi.org/10.1200/JCO.2015.64.8055
D’Amico, A.V., Chen, M.H., Renshaw, A., et al. (2015) Long-Term Follow-Up of a Randomized Trial of Radiation with or without Androgen Deprivation Therapy for Localized Prostate Cancer. JAMA, 314, 1291-1293. https://doi.org/10.1001/jama.2015.8577
Choquenet, C., et al. (1997) Survie des cancers de prostate avec métastases: 71 malades suivis de 7 à 11 ans. Progrès en Urologie, 7, 254-258.
Soerdjbalie-Maikoe, V., Pelger, R.C., Lycklama a Nijeholt, G.A., Arndt, J.W., et al. (2004) Bone Scintigraphy Predicts the Risk of Spinal Cord Compression in Hormone Refractory Prostate Cancer. European Journal of Nuclear Medicine and Molecular Imaging, 31, 958-963. https://doi.org/10.1007/s00259-004-1479-z
Inoue, T., Segawa, T., Kamba, T., Yoshimura, K., et al. (2009) Prevalence of Skeletal Complications and Their Impact on Survival of Hormone Refractory Prostate Cancer Patients in Japan. Urology, 73, 1104-1109. https://doi.org/10.1016/j.urology.2008.07.062
Smaletz, O., Scher, H.I., Small, E.J., et al. (2002) Nomogram for Overal Survival of Patients with Progressive Metastatic Prostate Cancer after Castration. Journal of Clinical Oncology, 20, 3972-3982. https://doi.org/10.1200/JCO.2002.11.021
Armstrong, A.J., Garrett-Mayer, E., de Wit, R., Tannock, I. and Eisenberger, M. (2010) Prediction of Survival Following First-Line Chemotherapy in Men with Castration-Resistant Metastatic Prostate Cancer. Clinical Cancer Research, 16, 203-211. https://doi.org/10.1158/1078-0432.CCR-09-2514
Metwalli, A.R., Rosner, I.L., Cullen, J., Chen, Y., Brand, T., Brassell, S.A., Lesperance, J., Porter, C., Sterbis, J. and Mc Leod, D.G. (2014) Elevated Alkaline Phosphatase Velocity Strongly Predicts Overall Survival and the Risk of Bone Metastases in Castrate-Resistant Prostate Cancer. Urologic Oncology, 32, 761. https://doi.org/10.1016/j.urolonc.2014.03.024
Moreira, D.M., Howard, L.E., Sourbeer, K.N., Amarasekara, H.S., Chow, L.C., Cockrell, D.C., Hanyok, B.T., Pratson, C.L., Aronson, W.J., Kane, C.J., et al. (2015) Predicting Bone Scan Positivity in Non-Metastatic Castration-Resistant Prostate Cancer. Prostate Cancer and Prostatic Diseases, 18, 333-337. https://doi.org/10.1038/pcan.2015.25